权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Community-viable screening for ASD in 9-month-old infants using quantitative eye-tracking assays of social visual engagement

使用社交视觉参与的定量眼动追踪分析对 9 个月大的婴儿进行社区可行的 ASD 筛查

基本信息

批准号：
10019596
负责人：
Warren Jones
金额：
$ 76.37万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-16 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10019596
关键词：
Affect Age Age-Months Agreement Biological Assay Blinded Child Childhood Clinical Communities Data Data Analytics Data Collection Development Developmental Delay Disorders Developmental Diagnostic Devices Diagnosis Diagnostic Diagnostic Sensitivity Dimensions Double-Blind Method Early Intervention Effectiveness Enrollment Evaluation General Population Goals Gold Improve Access Individual Infant Investigation Language Learning Measurement Measures Methodology Methods Modeling National Institute of Mental Health Neuronal Plasticity Outcome Performance Physicians Population Predictive Value Primary Health Care Procedures Reference Standards Research Design Risk Risk Assessment Sampling Screening procedure Sensitivity and Specificity Series Severities Specific qualifier value Specificity Standardization Symptoms Technology Testing Time Translations Validation Visit Visual autism spectrum disorder autistic base cognitive ability cognitive skill cohort cost effective design diagnosis standard disability efficacy testing experience indexing infancy instrument population based recruit response screening secondary analysis service intervention social tool visual tracking

项目摘要

PROJECT SUMMARY This project is in response to NIMH RFA-MH-19-120 calling for the development and validation of new screening methods for autism spectrum disorder (ASD) that can be used in infancy (0-12 months of age). We will deploy a cost-effective, high-throughput methodology utilizing performance-based, objective, and highly quantitative eye- tracking assays of social visual engagement—the way in which infants visually explore, engage, and ultimately learn from and adapt to their surrounding world—collected on a standalone, mobile eye-tracking data collection device, created in our lab (the Marcus Autism Center Investigational Device, MAC-ID). We will collect eye- tracking data from a population-based sample of N=2,000 9-month-old infants recruited consecutively in primary care practices at the time of their 9-month well-child visits. These infants will be followed longitudinally from 9 until 26 months for completion of a series of sequential screening and clinical ascertainment procedures designed to maximize sensitivity and achieve clinician-best-estimate diagnostic assignments of ASD vs. non- ASD and Affected [including ASD and non-ASD developmental delays] vs. Unaffected. We will measure the accuracy of eye-tracking-based screening at the age of 9 months relative to clinician best estimate diagnosis at 24 months (primary analysis), and we will measure dimensional agreement between eye-tracking assays at 9 months relative to outcome levels of social disability, verbal ability, and nonverbal cognitive ability (secondary analyses). Our overarching goal is to develop high-quality, objective, performance-based tools that can function as an effective and community-viable means of screening for ASD and other actionable developmental delays in infancy, to ultimately facilitate improved access to and benefit from early intervention.

项目总结